Integer Holdings Corporation stocks have been trading up by 20.96 percent after strong earnings and upbeat medical-device demand outlook.
What Traders Need To Know
- Freedom Capital initiated coverage on Integer Holdings with a Buy rating and a $112 price target, calling it a scaled, well-positioned specialty CDMO and treating an expected 2026 dip as temporary.
- Truist raised its price target on Integer from $97 to $110 and reiterated a Buy rating, even while pointing to weak sentiment, soft volumes, and muted capex across medtech.
- Truist Securities highlighted an overweight analyst consensus on Integer with a mean price target near $99.44.
- Citi lifted its price target on Integer Holdings to $96 from $92, kept a Neutral rating, and framed the stock as a potential catch-up trade in a jittery Q2 earnings setup.
- Integer Holdings scheduled its Q2 2026 earnings call, which could validate or challenge the recent wave of positive target revisions.
Weekly Update Jul 27 – Jul 31, 2026: On Friday, July 31, 2026 Integer Holdings Corporation stock [NYSE: ITGR] is trending up by 20.96%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Integer Holdings (ITGR) operates as a scaled specialty CDMO in medtech with solid fundamentals and mid‑teens historical revenue CAGR (8.7% 3‑yr, 12.4% 5‑yr). Margins are respectable but not best‑in‑class: gross margin 26%, EBITDA margin 18.8%, EBIT margin 10.8%, and net margin 7.6%, supporting a premium P/E of 34.5x and 1.8x sales. Balance sheet flexibility is adequate, with debt‑to‑equity 0.81x, interest coverage 8.4x, and strong liquidity (current ratio 3.8x, quick ratio 1.6x).
Technically, ITGR has broken out of its low‑100s range with a sharp weekly move to 121–122, confirming a strong uptrend and validating the recent analyst upgrades. The vertical spike suggests short covering and momentum buying, with intraday 5‑minute candles showing persistent bid support near 120 and elevated volume on up‑ticks. First actionable level is 120, which should be treated as near‑term support and a tactical add zone; a break below 116 would signal a failed breakout.
More Breaking News
- ABEV Stock Slumps As Bank Of America Turns Bearish
- NCPL Stock Holds Key Levels As Traders Study Volatile Chart
- NCPL Plunges As SEC Fraud Charges Ignite Class Actions
- Global Payments Stock Jumps As Analysts Hike Targets
Fundamentally, Street commentary (Freedom Capital, Truist, Citi) converges on a constructive multi‑year CDMO thesis, viewing any 2026 earnings dip as temporary. Versus broader Healthcare and MedTech equipment peers, ITGR trades at a modest growth premium but offers superior top‑line trajectory and sufficient balance sheet capacity for bolt‑on deals. Near term, the Q2 2026 call is the key catalyst. I see upside toward 130–135 over twelve months, with support at 116 and resistance now 125–130.
Quick Financial Overview
Integer Holdings Corporation (ITGR) just staged a major upside move. The weekly data show the stock pinned near $100 for several days, then ripping to around $122 on the latest print. That is a clean, high-range breakout above the prior band near $99–$101, backed by strong analyst catalysts from Freedom Capital, Truist, and Citi. For short-term traders, this type of expansion bar after a long base usually signals a fresh momentum leg, but it also raises the risk of sharp mean-reversion if news expectations get too hot.
On the intraday tape, ITGR traded in a tight $99–$101 range for most of the session before exploding from about $101 to over $123 in minutes, then cooling into the low $120s. That spike is classic “news-driven squeeze” behavior, with early shorts and late buyers both chasing. Price then consolidated between roughly $120.5 and $122 into the close, telling traders the market is trying to accept this new, higher value area rather than fully fading it.
Under the hood, Integer Holdings Corporation shows mid-teens EBITDA margins near 18.8% and EBIT margin around 10.8%, on annual revenue of roughly $1.85B and steady high-single to low-double-digit revenue growth. A P/E around 34.5 and price-to-sales near 1.8 put ITGR at a premium to slower industrial names but reasonable for a specialty medtech CDMO with gross margin of 26.4%. Balance sheet metrics like current ratio of 3.8, quick ratio of 1.6, and total debt-to-equity of 0.81 suggest the company is not stretched, though returns on equity in the high single digits show it is solid rather than elite in capital efficiency.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.